Trial Profile
Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Givinostat (Primary) ; Chlormethine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 18 Oct 2012 Planned number of patients changed from 21 to 23.
- 08 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.